Texas Medical Center offers this Web site, including all information, software, products and services available from this Web site or offered as part of or in conjunction with this Web site (the “Web site”), to you, the user, conditioned upon your acceptance of all of the terms, conditions, policies and notices stated here. Texas Medical

Patient Success Platform to unify and automate patient journeys for health systems, FQHCs, & specialty practices.

The first minimally invasive gallbladder ablation solution that gives patients the benefits of surgery, without the risk.

Babyscripts is the best-in-class risk detection platform to drive better clinical decision-making and care for moms anytime, anywhere.

Deep 6 AI is the leader in precision research software, connecting all research stakeholders in an AI-powered, real-time ecosystem.

Luma Health is a fast-growing health-tech company that provides a software platform and API tools to enable healthcare providers to dramatically improve the patient experience, truly unifying and automating the entire patient journey — access plus operational, clinical and financial. Luma’s Patient Success Platform makes it easy for people to make appointments, communicate with their

We bring together leaders within the Houston life science and healthcare ecosystem to help startups activate and access opportunities within the Texas Medical Center.

Alleviant Medical is focused on developing a novel minimally-invasive device to treat congestive heart failure. Our proprietary technology is designed to relieve heart failure symptoms, improve quality of life, and reduce hospital admissions for over 16 million patients currently suffering from this disease in the US and EU.

William McKeon is the President and Chief Executive Officer of the Texas Medical Center (TMC), the largest medical complex in the world. TMC is comprised of 60+ institutions, 120,000 employees, and an annual GDP of over $22 Billion. He is responsible for driving strategic, operational, and innovation initiatives to further TMC’s position as a global leader in life

Babyscripts’ market-leading pregnancy app is your digital front door to engage and remotely monitor pregnant & postpartum patients.

Marcus Nelson is the Vice President of Business Analytics at Texas Medical Center (TMC). In this role, he oversees all diligence for the TMC Venture Fund and leads strategic analyses for top initiatives. Marcus joined the Texas Medical Center in 2022. Marcus previously served as the Director of Strategy and Business Operations at a logistics

Briteseed is commercializing a new class of smart surgical tools that have artificial-vision assistance to help surgeons quickly identify landmarks and safely navigate vital structures. These multifunctional tools have the benefit of cautery, dissection, and optical tissue sensing in a single package.

John S. Reale, Jr. (JR) serves as Executive in Residence (EIR) at TMC Innovation. As EIR, he is an in-house resource for companies throughout the community. In addition, he advises the Healthcare Accelerator on strategy to advance how the TMC delivers value to its Member Institutions and entrepreneurs. JR also leads the TMC Venture Fund,

Clarium is building the next-gen supply chain platform that healthcare needs now. We proactively manage supply disruptions, identify substitutes, forecast surgical demand, optimize inventory planning and eliminate match exceptions ever-present in our volatile era. Our AI-enabled workflow and data tools are dramatically enhancing productivity for healthcare staff at forward-thinking institutions. All so they can focus

Tom Luby Ph.D. is the Director of Texas Medical Center (TMC) Innovation. In this role, he oversees all of the innovation efforts of TMC focused on research, education, and commercialization of novel healthcare solutions. Prior to this, he was the head of JLABS @ TMC in Houston, Texas. In that role, he catalyzes and support

CNSDose uses advanced genetic technology to fast-track finding the right antidepressant and dose. Genetically guided prescribing via CNSDose results in a 2.5 times greater likelihood of remission, which means faster recovery, reducing suffering and cutting costs that result from trial-and-error prescribing.

Gabrielle Guttman is the Business Strategy and Analytics Manager at TMC. In this role, she helps drive TMC’s strategic projects, including the Center for Device Innovation, as well as being an active member of the TMC Venture Fund. Prior to this, she worked at Johnson and Johnson Innovation as a Business Operations Manager at JLABS

CorInnova is developing a soft robotic heart assist device that gently squeezes the heart in synchrony with the heartbeat to increase output. Delivered minimally invasively, the device is designed to bring a new paradigm of treatment to the 95 percent of heart failure patients who are ineligible for existing cardiac devices.

Dr. Cohn is the Director for the Center of Device Innovation at the Texas Medical Center (TMC). He is also a professor of surgery at Baylor College of Medicine and an adjunct professor of Bioengineering at Rice University, the University of Houston and Texas A&M. Prior to joining TMC, he served as a Vice President

Deep 6 AI finds more, better matching patients for clinical trials in minutes rather than months by using artificial intelligence on clinical data.

Dr. Emily Reiser is the Associate Director of Texas Medical Center Innovation, spearheading the Accelerators for Cancer Therapeutics, Healthtech, and international BioBridge programs. Since joining TMC in 2019, she transitioned from direct engagement with startup founders to overseeing a vast stakeholder network and now leading the recruitment of entrepreneurs in residence. Prior to joining TMC,

Hamilton Health Box is the value-based primary care microclinic leader. HHB’s microclinic operating system leverages a hybrid primary care model to make healthcare accessible, convenient, and affordable for small footprint populations including small employers and rural populations. We aim to create healthier communities and reduce the total cost of healthcare through our high-touch primary care

At Ictero Medical, we are developing the CholeSafe System, the first minimally invasive treatment option that helps decrease complications and costs while providing definitive therapy to high risk surgical patients with gallstone disease. Unlike laparoscopic cholecystectomy, the CholeSafe System can be used in the interventional radiology suite with only minimal local anesthesia to defunctionalize the

Intelligent Implants is a bioelectronics company developing a revolutionary electrical stimulation platform technology that is incorporated into standard-of-care orthopedic implants. Its first product, SmartFuse, represents a novel method of delivering electric current to aid spinal fusion that can induce, direct, and monitor bone growth in real-time.

At Koda Health, we’re using AI to help guide difficult conversations in between providers and their elderly patients, starting with end-of-life healthcare.

LumaHealth’s cloud-based platform empowers healthcare providers with HIPAA-compliant, mobile-first SMS and secure chat communication tools that enable frictionless patient-provider conversations — including intelligent scheduling, referral management, actionable reminders, and care pathway messaging.

March Biosciences, Inc is a clinical-stage cell therapy company with a mission to transform patient care in the most challenging hematological malignancies. March Bio’s lead asset is at the end of Phase I trials for T-cell malignancies, diseases with a dismal prognosis that is currently unaddressed by CAR-T and targeted therapy technologies. The company’s pipeline

Medable is transforming healthcare by providing an enterprise platform for “Direct-to-Patient” clinical care and clinical trials, enabling patient generated data to drive healthcare delivery, research, and personalized and predictive medicine.

MIC is a software company that provides real time patient monitoring and predictive analytics across the continuum of care in the hospital. Its innovative SickbayTM platform archives, aggregates, and transforms short-lived, high-resolution waveform data across disparate devices to enable anywhere, anytime remote monitoring. MIC applies machine learning to develop predictive algorithms, laying the groundwork for

Motif Neurotech is powered by innovations in efficient wireless power and data, unlocking possibilities for new, miniature implants for tissue stimulation and diagnostic readings.

NarrativeDx uses AI to identify actionable insights from patient and provider feedback that improves patient satisfaction scores, increases operational efficiency and decreases employee turnover. Full details on the 2020 acquisition  here.

Noninvasix will be the first company to non-invasively monitor the severity of sepsis and septic shock, enabling clinicians to diagnose and monitor the response to treatment of tissue hypoxia in real-time. Noninvasix’s patented optoacoustic platform technology is the first solution to non-invasively and continuously measure central venous saturation. Incorporating Noninvasix into the ICU workflow allows

Building the future of early intervention in lung cancer.

Sonavex’s two FDA approved products, EchoMark and EchoSure, enable ultrasound based vascular monitoring to detect flow compromises earlier.

Surf Therapeutics is developing the first non-invasive ultrasound therapeutic platform for the treatment of autoimmune disorders.

Trusted Health is an opportunity platform for the modern nurse, connecting top RNs to flexible nursing jobs at innovation employers.

Vivifi Medical has developed the first suture-less laparoscopic technology that enables the connection of two vessels together for the treatment of Varicocele & Men’s Health Issues.

We’re a clinical-stage therapeutic medical device company that’s developed finely-tuned, bioabsorbable wraps intended to improve outcomes for the 5 million vascular surgeries performed each year.

Volumetric Biotechnologies is focused on innovations in volumetric imaging and biotechnology, such as 3D imaging, bioprinting, tissue engineering, or other fields reliant on volumetric data. Full details on the 2021 acquisition  here.